Provided by Tiger Trade Technology Pte. Ltd.

Organon & Co

8.21
+0.11001.36%
Post-market: 8.18-0.0269-0.33%19:23 EST
Volume:4.02M
Turnover:33.06M
Market Cap:2.13B
PE:4.29
High:8.43
Open:8.16
Low:7.98
Close:8.10
52wk High:17.23
52wk Low:6.18
Shares:259.98M
Float Shares:258.73M
Volume Ratio:0.82
T/O Rate:1.55%
Dividend:0.34
Dividend Rate:4.14%
EPS(TTM):1.91
EPS(LYR):3.33
ROE:71.62%
ROA:6.40%
PB:2.36
PE(LYR):2.47

Loading ...

Company Profile

Company Name:
Organon & Co
Exchange:
NYSE
Establishment Date:
1923
Employees:
10000
Office Location:
30 Hudson Street,Floor 33,Jersey City,New Jersey,United States
Zip Code:
07302
Fax:
- -
Introduction:
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Directors

Name
Position
Alan Ezekowitz
Independent Director
Carrie S. Cox
Interim Executive Chair, Independent Director
Cynthia M. Patton
Independent Director
Deborah Leone
Independent Director
Grace Puma
Independent Director
Helene Gayle
Independent Director
Philip Ozuah
Independent Director
Robert Essner
Lead Independent Director
Rochelle B. Lazarus
Independent Director
Shalini Sharp
Independent Director

Shareholders

Name
Position
Joseph Morrissey
Executive Vice President and Head of Manufacturing and Supply, Interim Chief Executive Officer
Matthew Walsh
Executive Vice President and Chief Financial Officer
Aaron Falcione
Executive Vice President and Chief Human Resources Officer
Daniel Karp
Executive Vice President, Corporate Development
Juan Camilo Arjona Ferreira
Executive Vice President, Head of Research & Development and Chief Medical Officer
Kirke Weaver
Executive Vice President, General Counsel and Corporate Secretary
Rachel Stahler
Executive Vice President and Chief Digital & Growth Officer
Vittorio Nisita
Executive Vice President and Head of Enterprise Services & Solutions